193 related articles for article (PubMed ID: 34438241)
21. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
22. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
23. The Systemic Management of Advanced Melanoma in 2016.
Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
[TBL] [Abstract][Full Text] [Related]
24. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
[TBL] [Abstract][Full Text] [Related]
25. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
[TBL] [Abstract][Full Text] [Related]
26. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
27. Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.
Spagnolo F; Picasso V; Lambertini M; Ottaviano V; Dozin B; Queirolo P
Cancer Treat Rev; 2016 Apr; 45():38-45. PubMed ID: 26975020
[TBL] [Abstract][Full Text] [Related]
28. Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Swe T; Kim KB
Clin Exp Metastasis; 2018 Aug; 35(5-6):503-520. PubMed ID: 30019239
[TBL] [Abstract][Full Text] [Related]
29. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
30. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
31. Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond.
Menzies AM; Long GV
Eur J Cancer; 2013 Oct; 49(15):3229-41. PubMed ID: 23870385
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report.
Kwatra V; Karanth NV; Priyadarshana K; Charakidis M
J Med Case Rep; 2017 Mar; 11(1):73. PubMed ID: 28315636
[TBL] [Abstract][Full Text] [Related]
33. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
34. Update on Immunotherapeutics in the Management of Metastatic Melanoma.
Bulir D; Liang S; O’Malley M; McWhirter E
Skin Therapy Lett; 2019 Jan; 24(1):8-11. PubMed ID: 30817881
[TBL] [Abstract][Full Text] [Related]
35. Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
Simon A; Kourie HR; Kerger J
Chin J Cancer; 2017 Jan; 36(1):10. PubMed ID: 28086948
[TBL] [Abstract][Full Text] [Related]
36. What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.
Mooradian MJ; Sullivan RJ
Oncology (Williston Park); 2019 Apr; 33(4):141-8. PubMed ID: 30990567
[TBL] [Abstract][Full Text] [Related]
37. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
38. [Great advances in the systemic treatment in malignant melanoma patients].
Ullenhag G; Hansson J; Ny L
Lakartidningen; 2017 May; 114():. PubMed ID: 28485771
[TBL] [Abstract][Full Text] [Related]
39. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
40. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.
Zhao CY; Hwang SJE; Wakade D; Carlos G; Anforth R; Fernández-Peñas P
Australas J Dermatol; 2017 Nov; 58(4):292-298. PubMed ID: 28707403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
